$ELV

Dixon Robert L JR sold $61K of ELV

Dixon Robert L JR sold 151 shares of Elevance Health, Inc. (ELV) at $401.77 on 2026-06-11.

Original reporting
SEC EDGAR · Dixon Robert L JR
Published Jun 12, 2026, 8:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Neutral
high confidence
Mentioned
$ELV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNeutralLow
01

Why it matters

The disclosure documents an open-market sale by a director; it does not include any new company performance, guidance, or regulatory/legal development.

02

Market read

Traders may note the insider sale, but the transaction size and lack of accompanying fundamental news make it unlikely to drive a sustained repricing.

03

What to watch

Director sales can be driven by diversification, taxes, or personal liquidity; without additional context, the signal-to-noise is low.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-12 for a sale executed 2026-06-11

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVNeutralHigh confidence
Context

Elevance Health director Robert L. Dixon Jr. filed an open-market sale of 151 shares at ~$401.77 on 2026-06-11 (Form 4).

Expected impact

Minimal near-term impact; any effect is likely noise unless paired with other negative disclosures.

Evidence & confidence

This is a small, non-10b5-1 open-market sale by a director with no accompanying company-specific catalyst or guidance change in the text.

Market effects

No sector read-through; single-company insider transaction with no operational/regulatory update.

None indicated.

None indicated.

Counterpoint

Because the filing notes no pre-arranged 10b5-1 plan, some traders may interpret it as a modest negative signal, even if the dollar amount is small.

Key entities

  • Elevance Health, Inc.

    Subject of the Form 4 insider transaction disclosure (ELV).

  • Robert L. Dixon Jr.

    Director who sold 151 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra